Table 1 Baseline characteristics of the study population
Variables, n (%) | Alectinib (n = 43) | Ceritinib (n = 22) | p-value |
|---|---|---|---|
Age, median (range), year | 62 (48 ~ 66) | 57 (54 ~ 74) | 0.501 |
Sex | |||
male | 19 (44.2) | 9 (40.9) | 1.000 |
female | 24 (55.8) | 13 (59.1) | |
Smoking history | |||
Smoker/ex-smoker | 8 (18.6) | 2 (9.1) | 0.520 |
Nonsmoker | 35 (81.4) | 20 (90.9) | |
ECOG PS | |||
0 /1 | 40 (93.0) | 20 (90.9) | 1.000 |
2/ 3 | 3 (7.0) | 2 (9.1) | |
Histology | |||
Adenocarcinoma | 43 (100.0) | 22 (100.0) | 1.000 |
Brain metastasis | |||
Yes | 13 (37.2) | 11 (50.0) | 0.426 |
No | 30 (62.8) | 11 (50.0) | |
Cause of crizotinib treatment failure | |||
Resistance | 26 (60.5) | 14 (63.6) | 1.000 |
Intolerance | 17 (39.5) | 8 (36.4) | |
Prior chemotherapy | |||
Yes | 12 (27.9) | 14 (63.6) | 0.012 |
No | 31 (72.1) | 8 (36.4) | |